|Bid||13.70 x 500|
|Ask||17.75 x 200|
|Day's Range||13.82 - 14.35|
|52 Week Range||7.02 - 18.50|
|PE Ratio (TTM)||-6.76|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||23.88|
CAMBRIDGE, Mass., Aug. 15, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced a leadership transition plan for its finance organization. ...
Q2 2017 Epizyme Inc Earnings Call
Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.